-3%

est. 2Y upside i

HealthcareSeries A

Rank

#3639

Sector

Health Care Technology

Est. Liquidity

~7Y

Data Quality

Data: Low

MediSage is a high-risk equity bet that a job candidate should approach with significant caution.

Last updated: May 13, 2026

Bull (15%)+150%

MediSage successfully closes a Series B at ~$90M valuation (2.6x current $34.7M) by 2027, driven by pharma contract scale with partners like AstraZeneca and expansion beyond India, growing revenue from $1.72M to $5M+. At 150% upside, this requires re-rating to ~18x forward revenue — achievable only if growth accelerates sharply from the current 13% YoY.

Base (43%)+15%

The company sustains 13–18% YoY growth and raises a modest bridge or flat Series B at a small premium to the $34.7M post-money valuation, generating ~15% mark-to-market upside before dilution haircut. Employee common stock sees negligible real gains as any new capital dilutes existing holders 20–25% and no liquidity event materializes within 2 years.

Bear (42%)-75%

With no follow-on capital since April 2022 and only $1.72M in revenue, MediSage exhausts runway and cannot raise at acceptable terms, forcing a down round or wind-down. Common stockholders absorb ~75% loss after the $7M preferred liquidation preference is satisfied first, leaving negligible residual value for employees.

Est. time to liquidity~7.0 years

Preference Stack Risk

high

Funding Intensity

20%

$7M in total preferred liquidation preferences represent 20.2% of the $34.7M valuation, meaning the first $7M of any exit proceeds flows entirely to preferred holders before common stockholders — including employees — receive anything.

Dilution Risk

high

With no funding since 2022 and $1.72M in revenue unlikely to sustain a 32-person team at market salaries, a future Series B or bridge will dilute existing common holders by an estimated 20–30%+.

Secondary Liquidity

none

As an Indian Series A company with $7M raised, no IPO signals, and no M&A signals, secondary market liquidity for employee equity is effectively zero over any 2-year horizon.

Questions to Ask at the Interview

Strategic questions based on MediSage's data — designed to show you've done your homework.

  • 1

    “MediSage has not publicly raised since the $7M Series A in April 2022 — what is the current cash runway, and are there active Series B conversations or term sheets in process?”

  • 2

    “What is the average contract value, contract duration, and net revenue retention rate with pharma partners like AstraZeneca and Sun Pharma, and how have those metrics trended over the last four quarters?”

  • 3

    “What is the current fully-diluted share count and the most recent 409A valuation, and how does the new-hire strike price compare to the $34.7M post-money valuation from 2022?”

Community

Valuation Sentiment

Our model estimates -3% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.